Miscellanées stupéfiantes et thérapeutiques, médicales et littéraires Jean-Yves Nau Revue Medicale Suisse, 2018, volume 14, 1110-1111 Stress post-traumatique : les vertus de l’ecstasyLe thérapeutique après le « récréatif » ? Dirigé par Michael C. Mithoefer (Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston), un groupe de chercheurs américains vient de publier dans The Lancet Psychiatry1 les résultats d’un essai clinique original ; un essai de phase II dans lequel la 3,4 méthylènedioxyméthamphétamine (MDMA) a été étudiée dans la prise en charge du syndrome de stress post-traumatique (SSPT) en complément de la psychothérapie. Le principe actif de l’ecstasy a été testé sur un petit groupe [...]
Lire la suiteExpériences de mort imminente: que va nous dévoiler la science? Jean-Yves Nau — 3 septembre 2018 http://www.slate.fr/story/166607/experiences-mort-imminente-science-drogue-psychedelique Des chercheurs viennent de reproduire, avec une drogue, ce que vivent certains malades. Les substances psychédéliques retrouvent du crédit dans la recherche médicale et scientifique. Et après ? | Joe Yates via Unsplash CC License by C’est une expérience spectaculaire qui n’est pas sans faire songer à celle d'Orphée et Eurydice. Conduite par des chercheurs du Psychedelic Research Group (Imperial College de Londres) et du Coma Science Group (Université de Liège) ses résultats viennent d’être publiés dans la revue en ligne Frontiers in Psychology. Ses auteurs et [...]
Lire la suiteNeuropathology of Drug Addictions and Substance Misuse Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects 2016, Pages 773-781 Chapter 72 - Use of LSD by Mental Health Professionals Petr Winkler, Ingmar Gorman, Rita Kočárová Doi : 10.1016/B978-0-12-800212-4.00072-8 Abstract This chapter focuses on self-experimentation with hallucinogens within the mental health sciences. Emphasis is given to the use of LSD by mental health professionals in the former Czechoslovakia. The text is based on four main data sources: (1) interviews with mental health professionals who experimented with LSD on themselves in the former Czechoslovakia; (2) scientific articles that were published in the time LSD research [...]
Lire la suiteCannabidiol regulation of emotion and emotional memory processing : relevance for treating anxiety-related and substance abuse disorders Jonathan L.C. Lee, Leandro J. Bertoglio, Francisco S. Guimarães and Carl W. Stevenson British Journal of Pharmacology, 2017, 174, 3242–3256 DOI : 10.1111/bph.13724 Abstract Learning to associate cues or contexts with potential threats or rewards is adaptive and enhances survival. Both aversive and appetitive memories are therefore powerful drivers of behaviour, but the inappropriate expression of conditioned responding to fear- and drug-related stimuli can develop into anxiety-related and substance abuse disorders respectively. These disorders are associated with abnormally persistent emotionalmemories and inadequate treatment, often leading to symptom relapse. [...]
Lire la suiteCannabidiol, a Cannabis sativa constituent, as an anxiolytic drug Alexandre Rafael de Mello Schier, Natalia Pinho de Oliveira Ribeiro, Adriana Cardoso de Oliveira e Silva, Jaime Eduardo Cecilio Hallak, José Alexandre S. Crippa, Antonio E. Nardi, Antonio Waldo Zuardi Revista Brasileira de Psiquiatria, 2012, 34 (Supl1), S104-S117 1516-4446 - ©2012 Elsevier Editora Ltda. All rights reserved. Abstract Objectives : To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. Method : The articles selected for the review were identified through searches in English, Portuguese, and Spanish in the electronic databases ISI [...]
Lire la suiteFluorinated Cannabidiol Derivatives : Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects Aviva Breuer, Christeene G. Haj, Manoela V. Fogaça, Felipe V. Gomes, Nicole, Rodrigues Silva, João Francisco Pedrazzi, Elaine A. Del Bel, Jaime C. Hallak, José, A. Crippa, Antonio W. Zuardi, Raphael Mechoulam, Francisco S. Guimarães PLOS ONE, Research Article, 2016 | DOI:10.1371/journal.pone.0158779 July 14, 2016 Abstract Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharmacological assays, including mice tests for anxiety, obsessive-compulsive disorder, depression and schizophrenia. In human trials [...]
Lire la suitePharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview G. M. Mandolini, M. Lazzaretti, A. Pigoni, L. Oldani, G. Delvecchio and P. Brambilla Epidemiology and Psychiatric Sciences, 2018, 27, 327–335. © Cambridge University Press 2018 doi : 10.1017/S2045796018000239 Abstract : Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic [...]
Lire la suiteCannabidiol as a Potential Treatment for Anxiety Disorders. Blessing E.M.; Steenkamp M.M.; Manzanares J.; Marmar C.R. Neurotherapeutics, 2015, 12, 4, 825-36 doi:10.1007/s13311-015-0387-1 (ISSN: 1878-7479) Abstract : Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, [...]
Lire la suiteCannabidiol in Anxiety and Sleep : A Large Case Series Scott Shannon, Nicole Lewis, Heather Lee, Shannon Hughes, The Permanente Journal, 2019, 23, 18-041 doi.org/10.7812/TPP/18-041 ABSTRACT Context : Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical [...]
Lire la suitePharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy James W. Wheless, · Dennis Dlugos, · Ian Miller, · D. Alexander Oh, · Neha Parikh, · Steven Phillips, · J. Ben Renfroe, · Colin M. Roberts, · Isra Saeed, · Steven P. Sparagana, · Jin Yu, · Maria Roberta Cilio, on behalf of the INS011-14-029 Study Investigators CNS Drugs, 2019 https://doi.org/10.1007/s40263-019-00624-4 Abstract Background : Prior studies have evaluated the use of various constituents of cannabis for their anti-seizure effects. Specifically, cannabidiol, a non-psychoactive component of cannabis, has been investigated for treatment-resistant epilepsy, but more information is needed particularly on [...]
Lire la suite